drugset / Trial / NCT04530981
A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST
NaSingle-groupOpen-labelTreatment
Summary
Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Substrate
Timeline
- Start
- 2021-09-22
- Primary completion
- 2023-11-16
- Completion
- 2024-07-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Repaglinide | Small molecule | 0.5 mg | Oral |
| Subject | Ripretinib | Small molecule | 150 mg | Oral |